Contact Us |

Search 

עברית  

    logoemp

 

slogN

 

 

dayanews emp nodaya

 

31 | July | 2014

Israel’s Ministry of Health Approves Pluristem’s Commercial-Scale 3D Cell Manufacturing Process Used at Its New Haifa Facility;

Read more >


22 | July | 2014

Pluristem to Host Investor Breakfast and Webcast on July 23 in New York City

Read more >


08 | July | 2014

Pluristem Initiates South Korean Arm of Multinational Phase II Intermittent Claudication Trial

Read more >


30 | June | 2014

Pluristem’s Ohad Karnieli to Deliver a Plenary Presentation on Cell Therapy Manufacturing at ISUS 2014 Conference

Read more >

 
 
 
About hp
 

Zami Aberman

Chairman and CEO

 

Zami Aberman

   From the CEO

Our vision at Pluristem Therapeutics is to leverage our position as a global leader in placenta-based cell science to become the world’s leader in developing and manufacturing cell therapy products. We believe our cutting edge technology can produce therapies that will become the standard of care for treating a host of inflammatory and ischemic conditions. We also believe “the process is the product.” This reflects our view that precise control of the entire process, from obtaining cells from the source, to delivery to the patient, is vital to the success of a cell therapy product. Our fully automated process, proprietary 3D cell expansion technology and increasing knowledge of the placental cell drive us towards the development of additional product candidates for new indications and markets.

 

On July 23 we hosted a Key Opinion Leader breakfast in New York. Dr. Baha Sibai, a world renowned expert in preeclampsia, Director of the Maternal-Fetal Medicine Fellowship Program and a Professor in the Department of Obstetrics and Gynecology at University of Texas Health Science Center, spoke about this serious complication of pregnancy, its heavy costs to society, and the potential of cell therapy to treat it. This tremendous unmet medical need makes this indication one of our top priorities at Pluristem and we are hopeful that the strong preclinical data we have accumulated using PLX-PAD in preeclampsia will translate into similar results in the clinic. If you would like to learn more about preeclampsia and Pluristem’s preeclampsia program, the recording of the webcast from the KOL event is above.

Zami Aberman
Chairman and CEO 

 

 

 

Share Button comm

  
Investors hp
 

     Yaky Yanay
     President and COO

 

Yaky Yanay

Pluristem's wholly owned subsidiary, Pluristem Ltd., has received approval for a 14.6 million New Israeli Shekel (approximately $ 4.2 million) grant from the Office of the Chief Scientist (OCS) within the Israeli Ministry of Economy. Once received, the grant will be used to cover R&D expenses for the period January 2014 to December 2014.

 

Read more >> 
 
 

Share Button comm

tech hp
 

Ohad Karnieli, Ph.D., MBA
VP Development & Manufacturing

 

Ohad Karnieli

Israel’s Ministry of Health Approves Pluristem’s Commercial-Scale 3D Cell Manufacturing Process Used at Its New Haifa Facility;

This follows clearances from U.S., E.U., German, and South Korean regulators

Pluristem has completed the approval process and received final clearance from a fifth regulatory agency for its 3D cell therapy manufacturing processes in use at its new facility in Haifa. The latest approval comes from Israel’s Ministry of Health and follows similar clearances from the U.S. Food and Drug Administration, the European Union’s Qualified Person, Germany’s Paul Ehrlich Institute, and the South Korean Ministry of Food and Drug Safety.

Read more >>

 
 

Share Button comm

 
 
Clinical Program hp
 

Esther Lukasiewicz Hagai, M.D., Ph.D.
VP Clinical & Medical Affairs

 

Esther Lukasiewicz Hagai

Pluristem Initiates South Korean Arm of Multinational Phase II Intermittent Claudication Trial

Trial now active in 13 clinical centers in 4 countries

Pluristem announced the initiation of South Korean sites in the Phase II study assessing PLacental eXpanded (PLX) cells in the treatment of intermittent claudication (IC).

Patient screening is now underway at three clinical centers, making South Korea the fourth country to participate in this randomized, double-blind, placebo-controlled Phase II trial.

The trial has been ongoing at clinical sites in the U.S., Israel and Germany with an enrollment target of 150 patients.
 

 Read more >>

 
 

Share Button comm

 

 catom 01

catom 03

catom 05

catom 07

catom 09

catom 11

catom 13

 

 

 

catom 02

Share Button